Onkure Therapeutics Inc
OKUR3.000USD
-0.100-3.23%
Fechamento 11/05, 16:00（ET）Cotações atrasadas em 15 min
40.59MValor de mercado
PerdaP/L TTM
Mais detalhes de Onkure Therapeutics Inc Empresa
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.
Informações de Onkure Therapeutics Inc
Código da empresaOKUR
Nome da EmpresaOnkure Therapeutics Inc
Data de listagemApr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
Número de funcionários46
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 09
Endereço6707 Winchester Circle, Suite 400
CidadeBOULDER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal80301
Telefone17203072892
Sitehttps://onkuretherapeutics.com/
Código da empresaOKUR
Data de listagemApr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
Executivos da empresa Onkure Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
15.32K
+56.70%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dylan Hartley, Ph.D.
Dr. Dylan Hartley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Ms. Valerie M. Jansen, M.D., Ph.D.
Ms. Valerie M. Jansen, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
15.32K
+56.70%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Acorn Capital Advisors, LLC
22.11%
Citadel Advisors LLC
8.48%
Shay Capital LLC
6.09%
The Vanguard Group, Inc.
5.50%
Cantor Fitzgerald, L.P
5.21%
Outro
52.60%
Investidores
Investidores
Proporção
Acorn Capital Advisors, LLC
22.11%
Citadel Advisors LLC
8.48%
Shay Capital LLC
6.09%
The Vanguard Group, Inc.
5.50%
Cantor Fitzgerald, L.P
5.21%
Outro
52.60%
Tipos de investidores
Investidores
Proporção
Investment Advisor
34.22%
Hedge Fund
24.32%
Investment Advisor/Hedge Fund
15.32%
Venture Capital
9.02%
Private Equity
3.83%
Individual Investor
1.73%
Research Firm
0.32%
Outro
11.25%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
177
11.18M
87.02%
-5.50M
2025Q2
186
12.83M
100.04%
-1.08M
2025Q1
187
12.71M
99.28%
-1.05M
2024Q4
190
12.64M
105.50%
+4.22M
2024Q3
172
2.79M
546.32%
-1.40M
2024Q2
171
3.11M
93.03%
-1.12M
2024Q1
161
3.05M
91.28%
-864.58K
2023Q4
152
2.81M
85.98%
-309.72K
2023Q3
128
3.01M
91.00%
-83.83K
2023Q2
119
2.90M
88.58%
+621.98K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Acorn Capital Advisors, LLC
2.84M
22.11%
--
--
Jun 30, 2025
Citadel Advisors LLC
1.09M
8.48%
+21.21K
+1.99%
Jun 30, 2025
Shay Capital LLC
782.05K
6.09%
-28.17K
-3.48%
Jun 30, 2025
The Vanguard Group, Inc.
706.73K
5.5%
--
--
Jun 30, 2025
Cantor Fitzgerald, L.P
669.54K
5.21%
+538.84K
+412.27%
Jun 30, 2025
Highbridge Capital Management, LLC
663.61K
5.17%
+224.81K
+51.23%
Jun 30, 2025
Vestal Point Capital, LP
635.00K
4.94%
--
--
Jun 30, 2025
StepStone Group LP
491.94K
3.83%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
478.55K
3.73%
--
--
Jun 30, 2025
BlackRock Financial Management, Inc.
463.59K
3.61%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
ALPS Medical Breakthroughs ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0%
iShares Russell 2000 ETF
Proporção0%
ProShares Ultra Nasdaq Biotechnology
Proporção0%
ALPS Medical Breakthroughs ETF
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
Global X Russell 2000 Covered Call ETF
Proporção0%
Invesco Nasdaq Biotechnology ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Global X Russell 2000 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Data
Tipo
Proporção
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
